ESTRO 2023 - Abstract Book

S1184

Digital Posters

ESTRO 2023

follow-up (4 w, 3 m, 6 m, 9 m, 12 m, 18 m, 24 m, 30 m, 36 m, 48 m, 60 m).

EPIC-26, EORTC QLQ-C30, and supplementary questions from QLQ-PR25 were used for PROMs assessing health-related quality of life. In this study results on urinary function, bowel habits, and sexual function are presented. Results The median follow-up was 23 (range 2 - 50) months and 93% of the patients received two years of bicalutamide. At BL, the median PSA was 0.2 (range <0.1- 4.1), the median age was 68 (range 50 - 75) years, and the median body mass index (BMI) was 27.5 (range 21.6 - 37.2). Charlson Comorbidity Index score >1 was found in 31.6% of the patients and 21% were still active smokers. The prevalence rate (PR) of problems with urinary function increased at EOT (p=0.044) and after 12 months of follow-up (p=0.029). In 13% of the patients a “moderate or big problem” was reported at BL, peaking at 34% nine months after EOT, and decreasing to 26% after one year. The PR of bleeding with urination were low (figure 1). The PR for bowel habit problems increased significantly at EOT (p=0.004) but after one year, there were no statistically significant differences in the parameters (p=0.776). The PR of a “moderate or big problem”, was 2% at BL, 8% at EOT, peaking at 9% four weeks after EOT (figure 2). Sixty percent reported a “moderate or big problem” regarding sexual dissatisfaction at BL, and PR showed only minor variations throughout the follow-up period (p=0.317 after one year) (figure 2).

Conclusion